Timothy Pluard, MD
Medical Oncology · Kansas City, MONPI 1396761698
Payments from drug & device makers
Across 1,698 payments — averaging $8677.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$6.4M
- Seagen Inc.$3.6M
- Novartis$2.3M
- Daiichi Sankyo Inc.$638K
- Merck$331K
- Sanofi US Services Inc.$280K
- plus $1.3M from 21 others
Across 26 payments — averaging $1458.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$24K
- Novartis$14K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer(2 entities) | 400 | $6,371,640 |
| Seagen Inc. | 495 | $3,603,411 |
| Novartis | 57 | $2,256,162 |
| Daiichi Sankyo Inc. | 170 | $637,946 |
| Merck | 5 | $330,925 |
| Sanofi US Services Inc. | 59 | $280,275 |
| Gilead | 140 | $223,511 |
| GSK | 52 | $184,454 |
| AstraZeneca | 48 | $113,031 |
| Exelixis Inc. | 77 | $107,579 |
| G1 Therapeutics, Inc. | 12 | $97,104 |
| Eli Lilly | 2 | $94,842 |
| Puma Biotechnology, Inc. | 15 | $74,599 |
| Jazz Pharmaceuticals Inc. | 32 | $61,041 |
| Stemline Therapeutics Inc. | 41 | $55,502 |
| Astrazeneca UK Limited | 5 | $53,537 |
| Genentech, Inc. | 23 | $44,743 |
| Genentech USA, Inc. | 32 | $39,765 |
| Macrogenics, Inc. | 8 | $39,358 |
| AbbVie | 15 | $30,473 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26,600 |
| Immunomedics, Inc. | 1 | $2,526 |
| Eisai Inc. | 2 | $2,099 |
| Amgen | 1 | $1,947 |
| Halozyme Inc | 1 | $900 |
| Myriad Genetic Laboratories, Inc. | 2 | $336 |
| Galvanize Therapeutics, Inc | 1 | $154 |
How this compares
$14,734,461 in reported general payments places this provider in the 95th percentile of 144 medical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Kansas City
- David BoudaKansas City$1.3M
- Nina Wagner JohnstonSaint Louis$22M
- Cynthia MaSaint Louis$22M
- Nancy BartlettSaint Louis$19.9M
- Douglas AdkinsSaint Louis$19.2M
- Ramaswamy GovindanSaint Louis$16.4M
- Kelly BoltonSaint Louis$14.5M
- Ravi VijSaint Louis$14.4M
- Daniel MorgenszternSaint Louis$12.8M
- Brad KahlSaint Louis$11.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.